Can the PFA-100® be modified to detect P2Y12 inhibition? [10]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 6, 2006, Pages 1424-1426

  Pidcock, M ^a   Harrison, Paul ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; AR C69931; CANGRELOR; CLOPIDOGREL; PURINE P2Y12 RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; N(6) METHYL 2' DEOXYADENOSINE 3',5' DIPHOSPHATE; N(6)-METHYL-2'-DEOXYADENOSINE 3',5'-DIPHOSPHATE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; TICLOPIDINE;

ANALYZER; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MONITORING; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LETTER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; DRUG ANTAGONISM; DRUG EFFECT; INSTRUMENTATION; METABOLISM; METHODOLOGY; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; BLOOD PLATELETS; DRUG MONITORING; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 33646811170     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01950.x     Document Type: Letter

References (19)

1. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
2. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005; 45: 1157-64.
3. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-11.
4. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005; 51: 957-65.
5. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-6.
6. Selvaraj CL, Van De Graaff EJ, Campbell CL, Abels BS, Marshall JP, Steinhubl SR. Point-of-care determination of baseline platelet function as a predictor of clinical outcomes in patients who present to the emergency department with chest pain. J Thromb Thrombolysis 2004; 18: 109-15.
7. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
8. Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-63.
9. Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin Chem Lab Med 2004; 42: 25-9.
10. Mueller T, Haltmayer M, Poelz W, Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 2003; 37: 117-23.
11. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002; 13: 493-7.
12. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004; 25: 476-83.
13. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: A case-crossover study. Stroke 2003; 34: 849-54.
14. Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2004; 2: 2278-9.
15. Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003; 34: 849-54.
16. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277-300.
17. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340-5.
18. Baurand A, Gachet C. The P2Y(1) receptor as a target for new antithrombotic drugs: A review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev 2003; 21: 67-76
19. Remijn JA, Wu YP, Jeninga EH, IJsseldijk MJ, van Willigen G, de Groot PG, Sixma JJ, Nurden AT, Nurden P. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686-91.